Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis-Reference-Cited by-同舟云学术

Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis

Published:2022-06-06 Issue:5 Volume:28 Page:702-712
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mancuso Maria Elisa¹^ORCID,Ingham Sheila J. M.²^ORCID,Kunze Marc³

Affiliation:

1. Center for Thrombosis and Hemorrhagic Diseases IRCCS Humanitas Research Hospital Rozzano Milan Italy

2. Bayer SA São Paulo Brazil

3. Bayer AG Berlin Germany

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14595

Reference36 articles.

1. Emerging therapies for hemophilia: controversies and unanswered questions;Arruda VR;F1000Res,2018

2. Treatment adherence in hemophilia

3. Haemophilia and Joint Disease: Pathophysiology, Evaluation, and Management

4. Non‐factor replacement therapy for haemophilia: a current update;Franchini M;Blood Transfus,2018

5. Inhibitors in congenital coagulation disorders

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives;Biomolecules;2024-07-15

2. Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice;Journal of Thrombosis and Haemostasis;2024-06

3. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies;Haemophilia;2024-03-13

4. TFPIα anticoagulant function is highly dependent on protein S in vivo;Science Advances;2024-02-02

5. Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas);Thrombosis Research;2023-11